Alpine Immune Sciences’ Lead Program ALPN-101 Demonstrates Preclinical Activity in Inflammatory Arthritis and Neurological Inflammation
Data from experimental models of inflammatory arthritis and
multiple sclerosis presented at 2018 ACR/ARHP Annual Meeting and 143rd
Annual Meeting of the
ALPN-101 has completed CMC scale up and is poised to be the first
“We continue to be encouraged by the emerging activity of ALPN-101 in
multiple inflammatory disease models. In particular, its superiority
over abatacept (CTLA4-Ig), an approved CD28 pathway inhibitor, strongly
supports its dual target rationale,” said
ALPN-101, a Dual ICOS/CD28 Antagonist, Potently Suppresses Disease in
Multiple Mouse Models of Autoimmunity (Poster #71873)
The preclinical studies presented at the ACR/ARHP Annual Meeting evaluated the activity of ALPN-101 in a collagen-induced arthritis (CIA) and an experimental autoimmune encephalomyelitis (EAE) model. Abatacept was used as a key comparator.
- ALPN-101, given preventively or therapeutically, significantly reduced disease activity in CIA.
ALPN-101 was more efficacious than interventions on the CD28 or
- In CIA, ALPN-101 inhibited multiple biomarkers associated with disease, including inflammatory cytokines, anti-collagen autoantibodies, and activated T cells.
Therapeutic Candidate ALPN-101, a Dual ICOS/CD28 Antagonist,
Demonstrates In Vivo Efficacy in an Experimental Autoimmune
Encephalomyelitis (EAE) Model (Poster #S254)
The preclinical study presented at the ANA Annual Meeting evaluated the activity of ALPN-101 in mouse EAE, a model for multiple sclerosis. Abatacept was also used as a comparator.
- ALPN-101 was superior to abatacept in reducing EAE as assessed by body weight and clinical scores.
- ALPN-101 reduced pro-inflammatory cytokines and activated T cells in vitro and in vivo.
Both posters are available on the company’s website at https://www.alpineimmunesciences.com/pipeline/autoimmune-inflammation/
This release contains forward-looking statements within the meaning
of Section 27A of the Securities Act of 1933, Section 21E of the
Securities Exchange Act of 1934 and the Private Securities Litigation
Reform Act of 1995. These forward-looking statements are not based on
historical fact, and include statements regarding Alpine’s platform
technology and potential therapies. Forward-looking statements generally
include statements that are predictive in nature and depend upon or
refer to future events or conditions, and include words such as “may,”
“will,” “should,” “would,” “expect,” “plan,” “intend,” and other similar
expressions among others. These forward-looking statements are based on
current assumptions that involve risks, uncertainties and other factors
that may cause actual results, events or developments to be materially
different from those expressed or implied by such forward-looking
statements. These risks and uncertainties, many of which are beyond our
control, include, but are not limited to: Alpine’s discovery-stage and
pre-clinical programs may not advance into the clinic or result in
approved products on a timely or cost-effective basis or at all; Alpine
may not achieve additional milestone payments pursuant to its
collaborations; the impact of competition; adverse conditions in the
general domestic and global economic markets; as well as the other risks
identified in Alpine’s filings with the
“Transmembrane Immunomodulatory Protein,” “TIP,” “Variant Ig Domain,”
“vIgD” and the Alpine logo are registered trademarks or trademarks of